Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Daniel Nava Rodrigues, … , Eliezer M. Van Allen, Johann S. de Bono


Corrigendum

Citation for this corrigendum: J Clin Invest. 2018;128(11):5185.
https://doi.org/10.1172/JCI125184 Charles L. Sawyers’s conflict-of-interest statement was not included in the manuscript. The correct statement is below. CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014. The authors regret the error.

Find the latest version:

http://jci.me/125184/pdf
Corrigendum

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer


Citation for this corrigendum: J Clin Invest. 2018;128(11):5185. https://doi.org/10.1172/JCI125184.

Charles L. Sawyers’s conflict-of-interest statement was not included in the manuscript. The correct statement is below.

CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014.

The authors regret the error.

Erratum

Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy


Citation for this erratum: J Clin Invest. 2018;128(11):5185. https://doi.org/10.1172/JCI124649.

In Table 2, the mutation for patient no. 11 in the column labeled “cDNA, aa change” is incorrect. The correct mutation is NM_002524.4:c.182A>G; NRAS p.(Q61R).

The JCI regrets the error.